The new device holds 900 units of long-acting insulin and delivers 160 units/mL of Toujeo insulin glargine in each injection, the insulin-maker touted.
“This new high capacity pen has a broader range of doses than the original SoloStar, delivering Toujeo, a long-acting insulin with established safety and efficacy,” Michelle Carnahan, head of Sanofi’s North America diabetes and cardiovascular division, said in prepared remarks.
“By reducing the number of injections for people who need more long-acting insulin and lowering copay costs – both of which are important to patients – Toujeo Max SoloStar underscores Sanofi’s continued commitment to help those living with diabetes,” Carnahan added.
In February, Sanofi touted data from its 10,000-patient Lightning study, which evaluated electronic medical records of adults with Type II diabetes to study its Toujeo injection.
The company found that Toujeo significantly lowered patients’ risk of experiencing severe low blood sugar compared to other long-acting insulin, like its own Lantus product.